semaglutide

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

OZEMPIC — NOVO, approved 2026-01-30 (NDA213051).

Most reported adverse events (US / FAERS)

61,731 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

nausea

9,513

off label use

6,280

vomiting

6,161

diarrhoea

5,718

decreased appetite

Medicines containing this active substance

5 medicines

🇺🇸 Also approved in the US (FDA)

OZEMPIC — NOVO, approved 2026-01-30 (NDA213051).

Most reported adverse events (US / FAERS)

61,731 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

nausea

9,513

off label use

6,280

vomiting

6,161

diarrhoea

5,718

decreased appetite

4,352

constipation

4,141

weight decreased

3,807

blood glucose increased

2,953

product use in unapproved indication

2,906

headache

2,816

impaired gastric emptying

2,796

fatigue

2,773

abdominal pain upper

2,642

wrong technique in product usage process

2,566

dizziness

2,307